Sign up to read this article for FREE!
After signing up, you'll start to receive regular news updates from us.
BioFocus Signs Integrated Drug Discovery Collaboration with Boehringer Ingelheim
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Galapagos announced that its BioFocus subsidiary signed a new collaboration agreement with Boehringer Ingelheim.
David Smith, CEO Galapagos Services, commented, “We are delighted to have secured this contract with Boehringer Ingelheim, one of the world’s leading research-based pharmaceutical companies and a new integrated drug discovery client to BioFocus. It is testament to the strength and depth of BioFocus’ drug discovery capabilities and expertise in this particular gene family.”
